Photo by freestocks on Unsplash
In 2022, the Swiss pharmaceutical industry transferred a substantial CHF218 million (equivalent to $243 million) to healthcare providers, including doctors, hospitals, and various medical professionals. This disclosure was made by 65 pharmaceutical companies, in line with their commitment to the Code of Pharmaceutical Cooperation, a practice initiated in 2015. Over the past eight years, these companies have collectively disbursed an impressive CHF 1.4 billion to support diverse healthcare-related activities.
Novartis, one of Switzerland's leading pharmaceutical companies, topped the list in 2022, with payments amounting to CHF31 million. This significant contribution underscores Novartis' dedication to advancing healthcare and fostering collaboration with the medical community.
Roche secured the second position on the list, with payments totalling CHF21.9 million, while the American pharmaceutical group Pfizer closely followed with CHF20 million in payments. These figures reflect the industry's commitment to supporting the vital work of healthcare providers
Transparency and accountability are at the core of this initiative. Swiss law mandates these payments, which primarily cover research, continuing education, consultancy services, and other essential healthcare activities. Importantly, the pharmaceutical industry is required to transparently list the recipients of these funds by name, ensuring ethical practices and accountability.
To ensure the accuracy and credibility of this disclosure, journalists from the respected Ringier Axel Springer publishing house meticulously evaluated the figures before publication. This collaboration between the pharmaceutical industry, media, and healthcare providers highlights Switzerland's dedication to upholding the highest standards of transparency and professionalism in the healthcare sector.
The Swiss pharmaceutical industry's commitment to transparency and collaboration with healthcare providers remains steadfast. By consistently disclosing financial contributions to the medical profession and hospitals, the industry aims to cultivate a culture of trust, innovation, and excellence in Swiss healthcare.
In conclusion, the Swiss pharmaceutical industry's disclosure of CHF218 million in payments to healthcare providers in 2022 is a clear demonstration of its commitment to advancing healthcare and promoting transparency. With Novartis leading the way and a rigorous evaluation process by Ringier Axel Springer, Switzerland continues to set an example for ethical and accountable practices in the pharmaceutical sector.
